PubMed:32219428 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":44,"end":52},"obj":"SP_7"},{"id":"T2","span":{"begin":71,"end":77},"obj":"UBERON:0001969"},{"id":"T3","span":{"begin":91,"end":102},"obj":"NCBITaxon:11118"},{"id":"T4","span":{"begin":117,"end":125},"obj":"SP_7"},{"id":"T5","span":{"begin":158,"end":176},"obj":"CHEBI:52217"},{"id":"T6","span":{"begin":158,"end":176},"obj":"CHEBI:52217"},{"id":"T7","span":{"begin":288,"end":294},"obj":"UBERON:0001969"},{"id":"T8","span":{"begin":374,"end":421},"obj":"SP_7"},{"id":"T9","span":{"begin":387,"end":398},"obj":"UBERON:0001004"},{"id":"T10","span":{"begin":423,"end":433},"obj":"SP_7"},{"id":"T11","span":{"begin":548,"end":556},"obj":"SP_7"},{"id":"T12","span":{"begin":567,"end":578},"obj":"UBERON:0001004"},{"id":"T13","span":{"begin":698,"end":703},"obj":"NCBITaxon:10239"},{"id":"T14","span":{"begin":738,"end":742},"obj":"PR:000012262"},{"id":"T15","span":{"begin":819,"end":825},"obj":"UBERON:0001969"},{"id":"T16","span":{"begin":1102,"end":1108},"obj":"UBERON:0001969"},{"id":"T17","span":{"begin":1181,"end":1187},"obj":"UBERON:0001969"},{"id":"T18","span":{"begin":1195,"end":1205},"obj":"SP_7"},{"id":"T19","span":{"begin":1215,"end":1223},"obj":"GO:0042571"},{"id":"T20","span":{"begin":1225,"end":1228},"obj":"GO:0071735"},{"id":"T21","span":{"begin":1465,"end":1473},"obj":"SP_7"},{"id":"T22","span":{"begin":1488,"end":1494},"obj":"UBERON:0001969"},{"id":"T23","span":{"begin":1620,"end":1625},"obj":"UBERON:0000062"},{"id":"T24","span":{"begin":1734,"end":1739},"obj":"NCBITaxon:10239"},{"id":"T25","span":{"begin":1746,"end":1751},"obj":"UBERON:0001977"},{"id":"T26","span":{"begin":1752,"end":1760},"obj":"GO:0042571"},{"id":"T27","span":{"begin":1776,"end":1781},"obj":"UBERON:0000178"},{"id":"T28","span":{"begin":1851,"end":1862},"obj":"GO:0015671"},{"id":"T29","span":{"begin":1909,"end":1915},"obj":"UBERON:0001969"},{"id":"T30","span":{"begin":2071,"end":2087},"obj":"CHEBI:22587"},{"id":"T31","span":{"begin":2071,"end":2087},"obj":"CHEBI:22587"},{"id":"T32","span":{"begin":2092,"end":2110},"obj":"DG_36"},{"id":"T33","span":{"begin":2122,"end":2128},"obj":"UBERON:0001969"},{"id":"T34","span":{"begin":2234,"end":2238},"obj":"PR:000012262"},{"id":"T35","span":{"begin":2401,"end":2411},"obj":"SP_7"},{"id":"T36","span":{"begin":2444,"end":2452},"obj":"GO:0042571"},{"id":"T37","span":{"begin":2946,"end":2954},"obj":"SP_7"},{"id":"T38","span":{"begin":2996,"end":3002},"obj":"UBERON:0001969"},{"id":"T39","span":{"begin":3027,"end":3035},"obj":"GO:0042571"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":78},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":79,"end":90},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":91,"end":203},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":204,"end":242},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":243,"end":253},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":254,"end":445},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":446,"end":480},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":481,"end":781},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":782,"end":838},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":839,"end":1039},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1040,"end":1121},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1122,"end":1132},"obj":"Sentence"},{"id":"TextSentencer_T13","span":{"begin":1133,"end":1474},"obj":"Sentence"},{"id":"TextSentencer_T14","span":{"begin":1475,"end":1551},"obj":"Sentence"},{"id":"TextSentencer_T15","span":{"begin":1552,"end":1579},"obj":"Sentence"},{"id":"TextSentencer_T16","span":{"begin":1580,"end":1928},"obj":"Sentence"},{"id":"TextSentencer_T17","span":{"begin":1929,"end":1937},"obj":"Sentence"},{"id":"TextSentencer_T18","span":{"begin":1938,"end":2111},"obj":"Sentence"},{"id":"TextSentencer_T19","span":{"begin":2112,"end":2311},"obj":"Sentence"},{"id":"TextSentencer_T20","span":{"begin":2312,"end":2538},"obj":"Sentence"},{"id":"TextSentencer_T21","span":{"begin":2539,"end":2680},"obj":"Sentence"},{"id":"TextSentencer_T22","span":{"begin":2681,"end":2757},"obj":"Sentence"},{"id":"TextSentencer_T23","span":{"begin":2758,"end":2839},"obj":"Sentence"},{"id":"TextSentencer_T24","span":{"begin":2840,"end":2866},"obj":"Sentence"},{"id":"TextSentencer_T25","span":{"begin":2867,"end":3089},"obj":"Sentence"},{"id":"TextSentencer_T26","span":{"begin":3090,"end":3277},"obj":"Sentence"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok1","span":{"begin":0,"end":9},"obj":"NNP"},{"id":"tok2","span":{"begin":10,"end":12},"obj":"IN"},{"id":"tok3","span":{"begin":13,"end":14},"obj":"CD"},{"id":"tok4","span":{"begin":15,"end":25},"obj":"NNP"},{"id":"tok5","span":{"begin":26,"end":29},"obj":"NNP"},{"id":"tok6","span":{"begin":30,"end":38},"obj":"NNS"},{"id":"tok7","span":{"begin":39,"end":43},"obj":"IN"},{"id":"tok8","span":{"begin":44,"end":50},"obj":"NNP"},{"id":"tok9","span":{"begin":50,"end":52},"obj":"CD"},{"id":"tok10","span":{"begin":53,"end":57},"obj":"IN"},{"id":"tok11","span":{"begin":58,"end":70},"obj":"NNP"},{"id":"tok12","span":{"begin":71,"end":77},"obj":"NNP"},{"id":"tok13","span":{"begin":77,"end":78},"obj":"."},{"id":"tok14","span":{"begin":79,"end":89},"obj":"NNP"},{"id":"tok15","span":{"begin":89,"end":90},"obj":":"},{"id":"tok16","span":{"begin":91,"end":102},"obj":"NNP"},{"id":"tok17","span":{"begin":103,"end":110},"obj":"NN"},{"id":"tok18","span":{"begin":111,"end":115},"obj":"CD"},{"id":"tok19","span":{"begin":116,"end":117},"obj":"("},{"id":"tok20","span":{"begin":117,"end":123},"obj":"NNP"},{"id":"tok21","span":{"begin":123,"end":125},"obj":"CD"},{"id":"tok22","span":{"begin":125,"end":126},"obj":")"},{"id":"tok23","span":{"begin":127,"end":129},"obj":"VBZ"},{"id":"tok24","span":{"begin":130,"end":131},"obj":"DT"},{"id":"tok25","span":{"begin":132,"end":140},"obj":"JJ"},{"id":"tok26","span":{"begin":141,"end":145},"obj":"IN"},{"id":"tok27","span":{"begin":146,"end":148},"obj":"DT"},{"id":"tok28","span":{"begin":149,"end":157},"obj":"JJ"},{"id":"tok29","span":{"begin":158,"end":169},"obj":"JJ"},{"id":"tok30","span":{"begin":170,"end":176},"obj":"NNS"},{"id":"tok31","span":{"begin":177,"end":180},"obj":"CC"},{"id":"tok32","span":{"begin":181,"end":192},"obj":"JJ"},{"id":"tok33","span":{"begin":193,"end":202},"obj":"NN"},{"id":"tok34","span":{"begin":202,"end":203},"obj":"."},{"id":"tok35","span":{"begin":204,"end":206},"obj":"PRP"},{"id":"tok36","span":{"begin":207,"end":209},"obj":"VBZ"},{"id":"tok37","span":{"begin":210,"end":218},"obj":"JJ"},{"id":"tok38","span":{"begin":219,"end":221},"obj":"TO"},{"id":"tok39","span":{"begin":222,"end":226},"obj":"VB"},{"id":"tok40","span":{"begin":227,"end":230},"obj":"JJ"},{"id":"tok41","span":{"begin":231,"end":241},"obj":"NNS"},{"id":"tok42","span":{"begin":241,"end":242},"obj":"."},{"id":"tok43","span":{"begin":243,"end":252},"obj":"NNP"},{"id":"tok44","span":{"begin":252,"end":253},"obj":":"},{"id":"tok45","span":{"begin":254,"end":256},"obj":"TO"},{"id":"tok46","span":{"begin":257,"end":266},"obj":"VB"},{"id":"tok47","span":{"begin":267,"end":274},"obj":"IN"},{"id":"tok48","span":{"begin":275,"end":287},"obj":"NN"},{"id":"tok49","span":{"begin":288,"end":294},"obj":"NN"},{"id":"tok50","span":{"begin":295,"end":306},"obj":"NN"},{"id":"tok51","span":{"begin":307,"end":310},"obj":"MD"},{"id":"tok52","span":{"begin":311,"end":313},"obj":"VB"},{"id":"tok53","span":{"begin":314,"end":324},"obj":"JJ"},{"id":"tok54","span":{"begin":325,"end":327},"obj":"IN"},{"id":"tok55","span":{"begin":328,"end":331},"obj":"DT"},{"id":"tok56","span":{"begin":332,"end":341},"obj":"NN"},{"id":"tok57","span":{"begin":342,"end":344},"obj":"IN"},{"id":"tok58","span":{"begin":345,"end":355},"obj":"RB"},{"id":"tok59","span":{"begin":356,"end":359},"obj":"JJ"},{"id":"tok60","span":{"begin":360,"end":368},"obj":"NNS"},{"id":"tok61","span":{"begin":369,"end":373},"obj":"IN"},{"id":"tok62","span":{"begin":374,"end":380},"obj":"JJ"},{"id":"tok63","span":{"begin":381,"end":386},"obj":"JJ"},{"id":"tok64","span":{"begin":387,"end":398},"obj":"JJ"},{"id":"tok65","span":{"begin":399,"end":407},"obj":"NN"},{"id":"tok66","span":{"begin":408,"end":419},"obj":"JJ"},{"id":"tok67","span":{"begin":420,"end":421},"obj":"CD"},{"id":"tok68","span":{"begin":422,"end":423},"obj":"("},{"id":"tok69","span":{"begin":423,"end":432},"obj":"NNP"},{"id":"tok70","span":{"begin":432,"end":433},"obj":"LS"},{"id":"tok71","span":{"begin":433,"end":434},"obj":")"},{"id":"tok72","span":{"begin":435,"end":444},"obj":"NN"},{"id":"tok73","span":{"begin":444,"end":445},"obj":"."},{"id":"tok74","span":{"begin":446,"end":452},"obj":"NNP"},{"id":"tok75","span":{"begin":452,"end":453},"obj":","},{"id":"tok76","span":{"begin":454,"end":461},"obj":"VBG"},{"id":"tok77","span":{"begin":461,"end":462},"obj":","},{"id":"tok78","span":{"begin":463,"end":466},"obj":"CC"},{"id":"tok79","span":{"begin":467,"end":479},"obj":"NNS"},{"id":"tok80","span":{"begin":479,"end":480},"obj":":"},{"id":"tok81","span":{"begin":481,"end":485},"obj":"NNP"},{"id":"tok82","span":{"begin":486,"end":492},"obj":"NN"},{"id":"tok83","span":{"begin":493,"end":495},"obj":"IN"},{"id":"tok84","span":{"begin":496,"end":497},"obj":"CD"},{"id":"tok85","span":{"begin":498,"end":508},"obj":"RB"},{"id":"tok86","span":{"begin":509,"end":512},"obj":"JJ"},{"id":"tok87","span":{"begin":513,"end":521},"obj":"NNS"},{"id":"tok88","span":{"begin":522,"end":526},"obj":"IN"},{"id":"tok89","span":{"begin":527,"end":547},"obj":"JJ"},{"id":"tok90","span":{"begin":548,"end":554},"obj":"NNP"},{"id":"tok91","span":{"begin":554,"end":556},"obj":"CD"},{"id":"tok92","span":{"begin":557,"end":560},"obj":"CC"},{"id":"tok93","span":{"begin":561,"end":566},"obj":"JJ"},{"id":"tok94","span":{"begin":567,"end":578},"obj":"JJ"},{"id":"tok95","span":{"begin":579,"end":587},"obj":"NN"},{"id":"tok96","span":{"begin":588,"end":596},"obj":"NN"},{"id":"tok97","span":{"begin":597,"end":598},"obj":"("},{"id":"tok98","span":{"begin":598,"end":602},"obj":"NNP"},{"id":"tok99","span":{"begin":602,"end":603},"obj":")"},{"id":"tok100","span":{"begin":604,"end":607},"obj":"WP"},{"id":"tok101","span":{"begin":608,"end":611},"obj":"VBD"},{"id":"tok102","span":{"begin":612,"end":615},"obj":"DT"},{"id":"tok103","span":{"begin":616,"end":625},"obj":"JJ"},{"id":"tok104","span":{"begin":626,"end":634},"obj":"NNS"},{"id":"tok105","span":{"begin":634,"end":635},"obj":":"},{"id":"tok106","span":{"begin":636,"end":642},"obj":"JJ"},{"id":"tok107","span":{"begin":643,"end":652},"obj":"NN"},{"id":"tok108","span":{"begin":653,"end":657},"obj":"IN"},{"id":"tok109","span":{"begin":658,"end":663},"obj":"JJ"},{"id":"tok110","span":{"begin":664,"end":675},"obj":"NN"},{"id":"tok111","span":{"begin":676,"end":679},"obj":"CC"},{"id":"tok112","span":{"begin":680,"end":692},"obj":"RB"},{"id":"tok113","span":{"begin":693,"end":697},"obj":"JJ"},{"id":"tok114","span":{"begin":698,"end":703},"obj":"JJ"},{"id":"tok115","span":{"begin":704,"end":708},"obj":"NN"},{"id":"tok116","span":{"begin":709,"end":716},"obj":"IN"},{"id":"tok117","span":{"begin":717,"end":726},"obj":"JJ"},{"id":"tok118","span":{"begin":727,"end":736},"obj":"NN"},{"id":"tok119","span":{"begin":736,"end":737},"obj":":"},{"id":"tok120","span":{"begin":738,"end":741},"obj":"NNP"},{"id":"tok121","span":{"begin":741,"end":742},"obj":"CD"},{"id":"tok122","span":{"begin":742,"end":743},"obj":"NN"},{"id":"tok123","span":{"begin":743,"end":746},"obj":"NNP"},{"id":"tok124","span":{"begin":746,"end":747},"obj":"CD"},{"id":"tok125","span":{"begin":748,"end":749},"obj":"NN"},{"id":"tok126","span":{"begin":749,"end":752},"obj":"CD"},{"id":"tok127","span":{"begin":752,"end":753},"obj":":"},{"id":"tok128","span":{"begin":754,"end":757},"obj":"CC"},{"id":"tok129","span":{"begin":758,"end":768},"obj":"JJ"},{"id":"tok130","span":{"begin":769,"end":780},"obj":"NN"},{"id":"tok131","span":{"begin":780,"end":781},"obj":"."},{"id":"tok132","span":{"begin":782,"end":785},"obj":"DT"},{"id":"tok133","span":{"begin":786,"end":787},"obj":"CD"},{"id":"tok134","span":{"begin":788,"end":792},"obj":"VBD"},{"id":"tok135","span":{"begin":793,"end":800},"obj":"VBN"},{"id":"tok136","span":{"begin":801,"end":805},"obj":"IN"},{"id":"tok137","span":{"begin":806,"end":818},"obj":"NN"},{"id":"tok138","span":{"begin":819,"end":825},"obj":"NN"},{"id":"tok139","span":{"begin":826,"end":837},"obj":"NN"},{"id":"tok140","span":{"begin":837,"end":838},"obj":"."},{"id":"tok141","span":{"begin":839,"end":842},"obj":"DT"},{"id":"tok142","span":{"begin":843,"end":848},"obj":"NN"},{"id":"tok143","span":{"begin":849,"end":852},"obj":"VBD"},{"id":"tok144","span":{"begin":853,"end":862},"obj":"VBN"},{"id":"tok145","span":{"begin":863,"end":865},"obj":"IN"},{"id":"tok146","span":{"begin":866,"end":869},"obj":"DT"},{"id":"tok147","span":{"begin":870,"end":880},"obj":"JJ"},{"id":"tok148","span":{"begin":881,"end":888},"obj":"NN"},{"id":"tok149","span":{"begin":889,"end":899},"obj":"NN"},{"id":"tok150","span":{"begin":899,"end":900},"obj":","},{"id":"tok151","span":{"begin":901,"end":909},"obj":"NNP"},{"id":"tok152","span":{"begin":910,"end":915},"obj":"NNP"},{"id":"tok153","span":{"begin":916,"end":922},"obj":"NNPS"},{"id":"tok154","span":{"begin":925,"end":933},"obj":"NNP"},{"id":"tok155","span":{"begin":934,"end":936},"obj":"IN"},{"id":"tok156","span":{"begin":937,"end":945},"obj":"NNP"},{"id":"tok157","span":{"begin":945,"end":946},"obj":","},{"id":"tok158","span":{"begin":947,"end":952},"obj":"NNP"},{"id":"tok159","span":{"begin":952,"end":953},"obj":","},{"id":"tok160","span":{"begin":954,"end":958},"obj":"IN"},{"id":"tok161","span":{"begin":959,"end":966},"obj":"NNP"},{"id":"tok162","span":{"begin":967,"end":969},"obj":"CD"},{"id":"tok163","span":{"begin":969,"end":970},"obj":","},{"id":"tok164","span":{"begin":971,"end":975},"obj":"CD"},{"id":"tok165","span":{"begin":975,"end":976},"obj":","},{"id":"tok166","span":{"begin":977,"end":979},"obj":"TO"},{"id":"tok167","span":{"begin":980,"end":985},"obj":"NNP"},{"id":"tok168","span":{"begin":986,"end":988},"obj":"CD"},{"id":"tok169","span":{"begin":988,"end":989},"obj":","},{"id":"tok170","span":{"begin":990,"end":994},"obj":"CD"},{"id":"tok171","span":{"begin":994,"end":995},"obj":":"},{"id":"tok172","span":{"begin":996,"end":1001},"obj":"JJ"},{"id":"tok173","span":{"begin":1002,"end":1006},"obj":"NN"},{"id":"tok174","span":{"begin":1007,"end":1009},"obj":"IN"},{"id":"tok175","span":{"begin":1010,"end":1019},"obj":"JJ"},{"id":"tok176","span":{"begin":1020,"end":1023},"obj":"VBD"},{"id":"tok177","span":{"begin":1024,"end":1029},"obj":"NNP"},{"id":"tok178","span":{"begin":1030,"end":1032},"obj":"CD"},{"id":"tok179","span":{"begin":1032,"end":1033},"obj":","},{"id":"tok180","span":{"begin":1034,"end":1038},"obj":"CD"},{"id":"tok181","span":{"begin":1038,"end":1039},"obj":"."},{"id":"tok182","span":{"begin":1040,"end":1048},"obj":"NNP"},{"id":"tok183","span":{"begin":1049,"end":1057},"obj":"NNS"},{"id":"tok184","span":{"begin":1058,"end":1062},"obj":"VBD"},{"id":"tok185","span":{"begin":1063,"end":1071},"obj":"VBN"},{"id":"tok186","span":{"begin":1072,"end":1078},"obj":"IN"},{"id":"tok187","span":{"begin":1079,"end":1082},"obj":"CC"},{"id":"tok188","span":{"begin":1083,"end":1088},"obj":"IN"},{"id":"tok189","span":{"begin":1089,"end":1101},"obj":"NN"},{"id":"tok190","span":{"begin":1102,"end":1108},"obj":"NN"},{"id":"tok191","span":{"begin":1109,"end":1120},"obj":"NN"},{"id":"tok192","span":{"begin":1120,"end":1121},"obj":"."},{"id":"tok193","span":{"begin":1122,"end":1131},"obj":"NNP"},{"id":"tok194","span":{"begin":1131,"end":1132},"obj":":"},{"id":"tok195","span":{"begin":1133,"end":1141},"obj":"NNS"},{"id":"tok196","span":{"begin":1142,"end":1150},"obj":"VBD"},{"id":"tok197","span":{"begin":1151,"end":1162},"obj":"NN"},{"id":"tok198","span":{"begin":1163,"end":1167},"obj":"IN"},{"id":"tok199","span":{"begin":1168,"end":1180},"obj":"NN"},{"id":"tok200","span":{"begin":1181,"end":1187},"obj":"NN"},{"id":"tok201","span":{"begin":1188,"end":1192},"obj":"IN"},{"id":"tok202","span":{"begin":1193,"end":1194},"obj":"DT"},{"id":"tok203","span":{"begin":1195,"end":1204},"obj":"NNP"},{"id":"tok204","span":{"begin":1204,"end":1205},"obj":"CD"},{"id":"tok205","span":{"begin":1205,"end":1206},"obj":":"},{"id":"tok206","span":{"begin":1206,"end":1214},"obj":"JJ"},{"id":"tok207","span":{"begin":1215,"end":1223},"obj":"NN"},{"id":"tok208","span":{"begin":1224,"end":1225},"obj":"("},{"id":"tok209","span":{"begin":1225,"end":1228},"obj":"NNP"},{"id":"tok210","span":{"begin":1228,"end":1229},"obj":")"},{"id":"tok211","span":{"begin":1230,"end":1237},"obj":"JJ"},{"id":"tok212","span":{"begin":1238,"end":1243},"obj":"NN"},{"id":"tok213","span":{"begin":1244,"end":1251},"obj":"JJR"},{"id":"tok214","span":{"begin":1252,"end":1256},"obj":"IN"},{"id":"tok215","span":{"begin":1257,"end":1258},"obj":"CD"},{"id":"tok216","span":{"begin":1258,"end":1259},"obj":":"},{"id":"tok217","span":{"begin":1259,"end":1263},"obj":"CD"},{"id":"tok218","span":{"begin":1264,"end":1265},"obj":"("},{"id":"tok219","span":{"begin":1265,"end":1268},"obj":"NN"},{"id":"tok220","span":{"begin":1269,"end":1274},"obj":"NN"},{"id":"tok221","span":{"begin":1275,"end":1283},"obj":"NN"},{"id":"tok222","span":{"begin":1284,"end":1289},"obj":"NN"},{"id":"tok223","span":{"begin":1289,"end":1290},"obj":","},{"id":"tok224","span":{"begin":1291,"end":1293},"obj":"IN"},{"id":"tok225","span":{"begin":1294,"end":1307},"obj":"JJ"},{"id":"tok226","span":{"begin":1308,"end":1321},"obj":"NN"},{"id":"tok227","span":{"begin":1322,"end":1327},"obj":"NN"},{"id":"tok228","span":{"begin":1328,"end":1329},"obj":"NN"},{"id":"tok229","span":{"begin":1329,"end":1334},"obj":"NNP"},{"id":"tok230","span":{"begin":1334,"end":1335},"obj":"NN"},{"id":"tok231","span":{"begin":1335,"end":1336},"obj":")"},{"id":"tok232","span":{"begin":1337,"end":1340},"obj":"CC"},{"id":"tok233","span":{"begin":1341,"end":1342},"obj":"DT"},{"id":"tok234","span":{"begin":1343,"end":1357},"obj":"NN"},{"id":"tok235","span":{"begin":1358,"end":1363},"obj":"NN"},{"id":"tok236","span":{"begin":1364,"end":1371},"obj":"JJR"},{"id":"tok237","span":{"begin":1372,"end":1376},"obj":"IN"},{"id":"tok238","span":{"begin":1377,"end":1379},"obj":"CD"},{"id":"tok239","span":{"begin":1380,"end":1381},"obj":"("},{"id":"tok240","span":{"begin":1381,"end":1384},"obj":"NN"},{"id":"tok241","span":{"begin":1385,"end":1390},"obj":"NN"},{"id":"tok242","span":{"begin":1391,"end":1399},"obj":"NN"},{"id":"tok243","span":{"begin":1400,"end":1405},"obj":"NN"},{"id":"tok244","span":{"begin":1405,"end":1406},"obj":")"},{"id":"tok245","span":{"begin":1407,"end":1411},"obj":"WDT"},{"id":"tok246","span":{"begin":1412,"end":1415},"obj":"VBD"},{"id":"tok247","span":{"begin":1416,"end":1420},"obj":"VBN"},{"id":"tok248","span":{"begin":1421,"end":1429},"obj":"VBN"},{"id":"tok249","span":{"begin":1430,"end":1434},"obj":"IN"},{"id":"tok250","span":{"begin":1435,"end":1436},"obj":"CD"},{"id":"tok251","span":{"begin":1437,"end":1445},"obj":"NNS"},{"id":"tok252","span":{"begin":1446,"end":1449},"obj":"WP"},{"id":"tok253","span":{"begin":1450,"end":1459},"obj":"VBD"},{"id":"tok254","span":{"begin":1460,"end":1464},"obj":"IN"},{"id":"tok255","span":{"begin":1465,"end":1471},"obj":"NNP"},{"id":"tok256","span":{"begin":1471,"end":1473},"obj":"CD"},{"id":"tok257","span":{"begin":1473,"end":1474},"obj":"."},{"id":"tok258","span":{"begin":1475,"end":1487},"obj":"NNP"},{"id":"tok259","span":{"begin":1488,"end":1494},"obj":"NN"},{"id":"tok260","span":{"begin":1495,"end":1498},"obj":"VBD"},{"id":"tok261","span":{"begin":1499,"end":1511},"obj":"VBN"},{"id":"tok262","span":{"begin":1512,"end":1519},"obj":"IN"},{"id":"tok263","span":{"begin":1520,"end":1522},"obj":"CD"},{"id":"tok264","span":{"begin":1523,"end":1526},"obj":"CC"},{"id":"tok265","span":{"begin":1527,"end":1529},"obj":"CD"},{"id":"tok266","span":{"begin":1530,"end":1534},"obj":"NNS"},{"id":"tok267","span":{"begin":1535,"end":1540},"obj":"IN"},{"id":"tok268","span":{"begin":1541,"end":1550},"obj":"NN"},{"id":"tok269","span":{"begin":1550,"end":1551},"obj":"."},{"id":"tok270","span":{"begin":1552,"end":1556},"obj":"NNP"},{"id":"tok271","span":{"begin":1557,"end":1565},"obj":"NNP"},{"id":"tok272","span":{"begin":1566,"end":1569},"obj":"CC"},{"id":"tok273","span":{"begin":1570,"end":1578},"obj":"NNS"},{"id":"tok274","span":{"begin":1578,"end":1579},"obj":":"},{"id":"tok275","span":{"begin":1580,"end":1587},"obj":"NNS"},{"id":"tok276","span":{"begin":1588,"end":1590},"obj":"IN"},{"id":"tok277","span":{"begin":1591,"end":1595},"obj":"NN"},{"id":"tok278","span":{"begin":1596,"end":1607},"obj":"NN"},{"id":"tok279","span":{"begin":1607,"end":1608},"obj":","},{"id":"tok280","span":{"begin":1609,"end":1619},"obj":"NNP"},{"id":"tok281","span":{"begin":1620,"end":1625},"obj":"NNP"},{"id":"tok282","span":{"begin":1626,"end":1633},"obj":"NN"},{"id":"tok283","span":{"begin":1634,"end":1644},"obj":"NNP"},{"id":"tok284","span":{"begin":1645,"end":1646},"obj":"("},{"id":"tok285","span":{"begin":1646,"end":1650},"obj":"NNP"},{"id":"tok286","span":{"begin":1650,"end":1651},"obj":")"},{"id":"tok287","span":{"begin":1652,"end":1657},"obj":"NN"},{"id":"tok288","span":{"begin":1658,"end":1659},"obj":"("},{"id":"tok289","span":{"begin":1659,"end":1664},"obj":"NN"},{"id":"tok290","span":{"begin":1665,"end":1666},"obj":"CD"},{"id":"tok291","span":{"begin":1666,"end":1667},"obj":":"},{"id":"tok292","span":{"begin":1667,"end":1669},"obj":"CD"},{"id":"tok293","span":{"begin":1669,"end":1670},"obj":","},{"id":"tok294","span":{"begin":1671,"end":1675},"obj":"IN"},{"id":"tok295","span":{"begin":1676,"end":1682},"obj":"JJR"},{"id":"tok296","span":{"begin":1683,"end":1689},"obj":"NNS"},{"id":"tok297","span":{"begin":1690,"end":1700},"obj":"VBG"},{"id":"tok298","span":{"begin":1701,"end":1705},"obj":"RBR"},{"id":"tok299","span":{"begin":1706,"end":1712},"obj":"JJ"},{"id":"tok300","span":{"begin":1713,"end":1720},"obj":"NN"},{"id":"tok301","span":{"begin":1720,"end":1721},"obj":")"},{"id":"tok302","span":{"begin":1721,"end":1722},"obj":","},{"id":"tok303","span":{"begin":1723,"end":1726},"obj":"NNP"},{"id":"tok304","span":{"begin":1726,"end":1727},"obj":"CD"},{"id":"tok305","span":{"begin":1727,"end":1728},"obj":"NN"},{"id":"tok306","span":{"begin":1728,"end":1731},"obj":"NNP"},{"id":"tok307","span":{"begin":1731,"end":1732},"obj":"CD"},{"id":"tok308","span":{"begin":1732,"end":1733},"obj":","},{"id":"tok309","span":{"begin":1734,"end":1739},"obj":"JJ"},{"id":"tok310","span":{"begin":1740,"end":1744},"obj":"NN"},{"id":"tok311","span":{"begin":1744,"end":1745},"obj":","},{"id":"tok312","span":{"begin":1746,"end":1751},"obj":"NN"},{"id":"tok313","span":{"begin":1752,"end":1760},"obj":"NN"},{"id":"tok314","span":{"begin":1761,"end":1766},"obj":"NN"},{"id":"tok315","span":{"begin":1766,"end":1767},"obj":","},{"id":"tok316","span":{"begin":1768,"end":1775},"obj":"JJ"},{"id":"tok317","span":{"begin":1776,"end":1781},"obj":"NN"},{"id":"tok318","span":{"begin":1782,"end":1793},"obj":"JJ"},{"id":"tok319","span":{"begin":1794,"end":1799},"obj":"NN"},{"id":"tok320","span":{"begin":1799,"end":1800},"obj":","},{"id":"tok321","span":{"begin":1801,"end":1805},"obj":"NNP"},{"id":"tok322","span":{"begin":1805,"end":1806},"obj":","},{"id":"tok323","span":{"begin":1807,"end":1810},"obj":"CC"},{"id":"tok324","span":{"begin":1811,"end":1822},"obj":"NN"},{"id":"tok325","span":{"begin":1823,"end":1826},"obj":"CC"},{"id":"tok326","span":{"begin":1827,"end":1841},"obj":"NN"},{"id":"tok327","span":{"begin":1842,"end":1850},"obj":"NN"},{"id":"tok328","span":{"begin":1851,"end":1862},"obj":"NN"},{"id":"tok329","span":{"begin":1863,"end":1864},"obj":"("},{"id":"tok330","span":{"begin":1864,"end":1868},"obj":"NNP"},{"id":"tok331","span":{"begin":1868,"end":1869},"obj":")"},{"id":"tok332","span":{"begin":1870,"end":1878},"obj":"VBZ"},{"id":"tok333","span":{"begin":1879,"end":1885},"obj":"IN"},{"id":"tok334","span":{"begin":1886,"end":1889},"obj":"CC"},{"id":"tok335","span":{"begin":1890,"end":1895},"obj":"IN"},{"id":"tok336","span":{"begin":1896,"end":1908},"obj":"NN"},{"id":"tok337","span":{"begin":1909,"end":1915},"obj":"NN"},{"id":"tok338","span":{"begin":1916,"end":1927},"obj":"NN"},{"id":"tok339","span":{"begin":1927,"end":1928},"obj":"."},{"id":"tok340","span":{"begin":1929,"end":1936},"obj":"NNS"},{"id":"tok341","span":{"begin":1936,"end":1937},"obj":":"},{"id":"tok342","span":{"begin":1938,"end":1941},"obj":"DT"},{"id":"tok343","span":{"begin":1942,"end":1943},"obj":"CD"},{"id":"tok344","span":{"begin":1944,"end":1952},"obj":"NNS"},{"id":"tok345","span":{"begin":1953,"end":1954},"obj":"("},{"id":"tok346","span":{"begin":1954,"end":1957},"obj":"NN"},{"id":"tok347","span":{"begin":1958,"end":1963},"obj":"NN"},{"id":"tok348","span":{"begin":1963,"end":1964},"obj":","},{"id":"tok349","span":{"begin":1965,"end":1967},"obj":"CD"},{"id":"tok350","span":{"begin":1967,"end":1968},"obj":":"},{"id":"tok351","span":{"begin":1968,"end":1970},"obj":"CD"},{"id":"tok352","span":{"begin":1971,"end":1976},"obj":"NNS"},{"id":"tok353","span":{"begin":1976,"end":1977},"obj":":"},{"id":"tok354","span":{"begin":1978,"end":1979},"obj":"CD"},{"id":"tok355","span":{"begin":1980,"end":1985},"obj":"NNS"},{"id":"tok356","span":{"begin":1985,"end":1986},"obj":")"},{"id":"tok357","span":{"begin":1987,"end":1991},"obj":"VBD"},{"id":"tok358","span":{"begin":1992,"end":2001},"obj":"VBG"},{"id":"tok359","span":{"begin":2002,"end":2012},"obj":"JJ"},{"id":"tok360","span":{"begin":2013,"end":2024},"obj":"NN"},{"id":"tok361","span":{"begin":2025,"end":2027},"obj":"IN"},{"id":"tok362","span":{"begin":2028,"end":2031},"obj":"DT"},{"id":"tok363","span":{"begin":2032,"end":2036},"obj":"NN"},{"id":"tok364","span":{"begin":2037,"end":2039},"obj":"IN"},{"id":"tok365","span":{"begin":2040,"end":2049},"obj":"NN"},{"id":"tok366","span":{"begin":2050,"end":2053},"obj":"CC"},{"id":"tok367","span":{"begin":2054,"end":2057},"obj":"DT"},{"id":"tok368","span":{"begin":2058,"end":2061},"obj":"VBD"},{"id":"tok369","span":{"begin":2062,"end":2070},"obj":"VBN"},{"id":"tok370","span":{"begin":2071,"end":2080},"obj":"JJ"},{"id":"tok371","span":{"begin":2081,"end":2087},"obj":"NNS"},{"id":"tok372","span":{"begin":2088,"end":2091},"obj":"CC"},{"id":"tok373","span":{"begin":2092,"end":2110},"obj":"NN"},{"id":"tok374","span":{"begin":2110,"end":2111},"obj":"."},{"id":"tok375","span":{"begin":2112,"end":2121},"obj":"VBG"},{"id":"tok376","span":{"begin":2122,"end":2128},"obj":"NN"},{"id":"tok377","span":{"begin":2129,"end":2140},"obj":"NN"},{"id":"tok378","span":{"begin":2140,"end":2141},"obj":","},{"id":"tok379","span":{"begin":2142,"end":2146},"obj":"NN"},{"id":"tok380","span":{"begin":2147,"end":2158},"obj":"NN"},{"id":"tok381","span":{"begin":2159,"end":2169},"obj":"JJ"},{"id":"tok382","span":{"begin":2170,"end":2176},"obj":"IN"},{"id":"tok383","span":{"begin":2177,"end":2178},"obj":"CD"},{"id":"tok384","span":{"begin":2179,"end":2183},"obj":"NNS"},{"id":"tok385","span":{"begin":2184,"end":2186},"obj":"IN"},{"id":"tok386","span":{"begin":2187,"end":2188},"obj":"CD"},{"id":"tok387","span":{"begin":2189,"end":2191},"obj":"IN"},{"id":"tok388","span":{"begin":2192,"end":2193},"obj":"CD"},{"id":"tok389","span":{"begin":2194,"end":2202},"obj":"NNS"},{"id":"tok390","span":{"begin":2202,"end":2203},"obj":","},{"id":"tok391","span":{"begin":2204,"end":2207},"obj":"DT"},{"id":"tok392","span":{"begin":2208,"end":2212},"obj":"NNP"},{"id":"tok393","span":{"begin":2213,"end":2218},"obj":"NN"},{"id":"tok394","span":{"begin":2219,"end":2228},"obj":"VBD"},{"id":"tok395","span":{"begin":2228,"end":2229},"obj":","},{"id":"tok396","span":{"begin":2230,"end":2233},"obj":"CC"},{"id":"tok397","span":{"begin":2234,"end":2237},"obj":"NNP"},{"id":"tok398","span":{"begin":2237,"end":2238},"obj":"CD"},{"id":"tok399","span":{"begin":2238,"end":2239},"obj":"NN"},{"id":"tok400","span":{"begin":2239,"end":2242},"obj":"NNP"},{"id":"tok401","span":{"begin":2242,"end":2243},"obj":"CD"},{"id":"tok402","span":{"begin":2244,"end":2253},"obj":"VBN"},{"id":"tok403","span":{"begin":2254,"end":2260},"obj":"IN"},{"id":"tok404","span":{"begin":2261,"end":2263},"obj":"CD"},{"id":"tok405","span":{"begin":2264,"end":2268},"obj":"NNS"},{"id":"tok406","span":{"begin":2269,"end":2270},"obj":"("},{"id":"tok407","span":{"begin":2270,"end":2275},"obj":"NN"},{"id":"tok408","span":{"begin":2275,"end":2276},"obj":","},{"id":"tok409","span":{"begin":2277,"end":2280},"obj":"CD"},{"id":"tok410","span":{"begin":2280,"end":2281},"obj":":"},{"id":"tok411","span":{"begin":2281,"end":2284},"obj":"CD"},{"id":"tok412","span":{"begin":2285,"end":2291},"obj":"IN"},{"id":"tok413","span":{"begin":2292,"end":2295},"obj":"CC"},{"id":"tok414","span":{"begin":2296,"end":2299},"obj":"CD"},{"id":"tok415","span":{"begin":2299,"end":2300},"obj":":"},{"id":"tok416","span":{"begin":2300,"end":2303},"obj":"CD"},{"id":"tok417","span":{"begin":2304,"end":2309},"obj":"IN"},{"id":"tok418","span":{"begin":2309,"end":2310},"obj":")"},{"id":"tok419","span":{"begin":2310,"end":2311},"obj":"."},{"id":"tok420","span":{"begin":2312,"end":2317},"obj":"NNP"},{"id":"tok421","span":{"begin":2318,"end":2323},"obj":"NNS"},{"id":"tok422","span":{"begin":2324,"end":2328},"obj":"RB"},{"id":"tok423","span":{"begin":2329,"end":2338},"obj":"VBD"},{"id":"tok424","span":{"begin":2339,"end":2342},"obj":"CC"},{"id":"tok425","span":{"begin":2343,"end":2349},"obj":"VBD"},{"id":"tok426","span":{"begin":2350,"end":2358},"obj":"JJ"},{"id":"tok427","span":{"begin":2359,"end":2365},"obj":"IN"},{"id":"tok428","span":{"begin":2366,"end":2368},"obj":"CD"},{"id":"tok429","span":{"begin":2369,"end":2373},"obj":"NNS"},{"id":"tok430","span":{"begin":2374,"end":2379},"obj":"IN"},{"id":"tok431","span":{"begin":2380,"end":2383},"obj":"DT"},{"id":"tok432","span":{"begin":2384,"end":2395},"obj":"NN"},{"id":"tok433","span":{"begin":2395,"end":2396},"obj":","},{"id":"tok434","span":{"begin":2397,"end":2400},"obj":"CC"},{"id":"tok435","span":{"begin":2401,"end":2410},"obj":"NNP"},{"id":"tok436","span":{"begin":2410,"end":2411},"obj":"CD"},{"id":"tok437","span":{"begin":2411,"end":2412},"obj":":"},{"id":"tok438","span":{"begin":2412,"end":2420},"obj":"JJ"},{"id":"tok439","span":{"begin":2421,"end":2426},"obj":"NNP"},{"id":"tok440","span":{"begin":2427,"end":2430},"obj":"CC"},{"id":"tok441","span":{"begin":2431,"end":2443},"obj":"VBG"},{"id":"tok442","span":{"begin":2444,"end":2452},"obj":"NN"},{"id":"tok443","span":{"begin":2453,"end":2459},"obj":"NNS"},{"id":"tok444","span":{"begin":2460,"end":2469},"obj":"VBD"},{"id":"tok445","span":{"begin":2470,"end":2479},"obj":"VBG"},{"id":"tok446","span":{"begin":2480,"end":2483},"obj":"DT"},{"id":"tok447","span":{"begin":2484,"end":2495},"obj":"NN"},{"id":"tok448","span":{"begin":2496,"end":2497},"obj":"("},{"id":"tok449","span":{"begin":2497,"end":2502},"obj":"NN"},{"id":"tok450","span":{"begin":2502,"end":2503},"obj":","},{"id":"tok451","span":{"begin":2504,"end":2506},"obj":"CD"},{"id":"tok452","span":{"begin":2506,"end":2507},"obj":":"},{"id":"tok453","span":{"begin":2507,"end":2509},"obj":"CD"},{"id":"tok454","span":{"begin":2510,"end":2516},"obj":"IN"},{"id":"tok455","span":{"begin":2517,"end":2520},"obj":"CC"},{"id":"tok456","span":{"begin":2521,"end":2523},"obj":"CD"},{"id":"tok457","span":{"begin":2523,"end":2524},"obj":":"},{"id":"tok458","span":{"begin":2524,"end":2527},"obj":"CD"},{"id":"tok459","span":{"begin":2528,"end":2530},"obj":"IN"},{"id":"tok460","span":{"begin":2531,"end":2534},"obj":"NN"},{"id":"tok461","span":{"begin":2535,"end":2536},"obj":"CD"},{"id":"tok462","span":{"begin":2536,"end":2537},"obj":")"},{"id":"tok463","span":{"begin":2537,"end":2538},"obj":"."},{"id":"tok464","span":{"begin":2539,"end":2543},"obj":"NNP"},{"id":"tok465","span":{"begin":2544,"end":2552},"obj":"VBD"},{"id":"tok466","span":{"begin":2553,"end":2555},"obj":"IN"},{"id":"tok467","span":{"begin":2556,"end":2557},"obj":"CD"},{"id":"tok468","span":{"begin":2558,"end":2566},"obj":"NNS"},{"id":"tok469","span":{"begin":2567,"end":2569},"obj":"IN"},{"id":"tok470","span":{"begin":2570,"end":2572},"obj":"CD"},{"id":"tok471","span":{"begin":2573,"end":2577},"obj":"NNS"},{"id":"tok472","span":{"begin":2578,"end":2583},"obj":"IN"},{"id":"tok473","span":{"begin":2584,"end":2595},"obj":"NN"},{"id":"tok474","span":{"begin":2595,"end":2596},"obj":","},{"id":"tok475","span":{"begin":2597,"end":2600},"obj":"CC"},{"id":"tok476","span":{"begin":2601,"end":2602},"obj":"CD"},{"id":"tok477","span":{"begin":2603,"end":2611},"obj":"NNS"},{"id":"tok478","span":{"begin":2612,"end":2616},"obj":"VBD"},{"id":"tok479","span":{"begin":2617,"end":2623},"obj":"JJ"},{"id":"tok480","span":{"begin":2624,"end":2628},"obj":"IN"},{"id":"tok481","span":{"begin":2629,"end":2639},"obj":"JJ"},{"id":"tok482","span":{"begin":2640,"end":2651},"obj":"NN"},{"id":"tok483","span":{"begin":2652,"end":2658},"obj":"IN"},{"id":"tok484","span":{"begin":2659,"end":2660},"obj":"CD"},{"id":"tok485","span":{"begin":2661,"end":2666},"obj":"NNS"},{"id":"tok486","span":{"begin":2667,"end":2669},"obj":"IN"},{"id":"tok487","span":{"begin":2670,"end":2679},"obj":"NN"},{"id":"tok488","span":{"begin":2679,"end":2680},"obj":"."},{"id":"tok489","span":{"begin":2681,"end":2683},"obj":"IN"},{"id":"tok490","span":{"begin":2684,"end":2687},"obj":"DT"},{"id":"tok491","span":{"begin":2688,"end":2689},"obj":"CD"},{"id":"tok492","span":{"begin":2690,"end":2698},"obj":"NNS"},{"id":"tok493","span":{"begin":2698,"end":2699},"obj":","},{"id":"tok494","span":{"begin":2700,"end":2701},"obj":"CD"},{"id":"tok495","span":{"begin":2702,"end":2706},"obj":"VBP"},{"id":"tok496","span":{"begin":2707,"end":2711},"obj":"VBN"},{"id":"tok497","span":{"begin":2712,"end":2722},"obj":"VBN"},{"id":"tok498","span":{"begin":2723,"end":2727},"obj":"IN"},{"id":"tok499","span":{"begin":2728,"end":2731},"obj":"DT"},{"id":"tok500","span":{"begin":2732,"end":2740},"obj":"NN"},{"id":"tok501","span":{"begin":2741,"end":2742},"obj":"("},{"id":"tok502","span":{"begin":2742,"end":2748},"obj":"NN"},{"id":"tok503","span":{"begin":2749,"end":2751},"obj":"IN"},{"id":"tok504","span":{"begin":2752,"end":2756},"obj":"NN"},{"id":"tok505","span":{"begin":2756,"end":2757},"obj":":"},{"id":"tok506","span":{"begin":2758,"end":2760},"obj":"CD"},{"id":"tok507","span":{"begin":2760,"end":2761},"obj":","},{"id":"tok508","span":{"begin":2762,"end":2764},"obj":"CD"},{"id":"tok509","span":{"begin":2764,"end":2765},"obj":","},{"id":"tok510","span":{"begin":2766,"end":2769},"obj":"CC"},{"id":"tok511","span":{"begin":2770,"end":2772},"obj":"CD"},{"id":"tok512","span":{"begin":2773,"end":2777},"obj":"NNS"},{"id":"tok513","span":{"begin":2777,"end":2778},"obj":")"},{"id":"tok514","span":{"begin":2778,"end":2779},"obj":","},{"id":"tok515","span":{"begin":2780,"end":2783},"obj":"CC"},{"id":"tok516","span":{"begin":2784,"end":2785},"obj":"CD"},{"id":"tok517","span":{"begin":2786,"end":2789},"obj":"VBP"},{"id":"tok518","span":{"begin":2790,"end":2792},"obj":"IN"},{"id":"tok519","span":{"begin":2793,"end":2799},"obj":"JJ"},{"id":"tok520","span":{"begin":2800,"end":2809},"obj":"NN"},{"id":"tok521","span":{"begin":2810,"end":2812},"obj":"IN"},{"id":"tok522","span":{"begin":2813,"end":2815},"obj":"CD"},{"id":"tok523","span":{"begin":2816,"end":2820},"obj":"NNS"},{"id":"tok524","span":{"begin":2821,"end":2826},"obj":"IN"},{"id":"tok525","span":{"begin":2827,"end":2838},"obj":"NN"},{"id":"tok526","span":{"begin":2838,"end":2839},"obj":"."},{"id":"tok527","span":{"begin":2840,"end":2851},"obj":"NNP"},{"id":"tok528","span":{"begin":2852,"end":2855},"obj":"CC"},{"id":"tok529","span":{"begin":2856,"end":2865},"obj":"NNP"},{"id":"tok530","span":{"begin":2865,"end":2866},"obj":":"},{"id":"tok531","span":{"begin":2867,"end":2869},"obj":"IN"},{"id":"tok532","span":{"begin":2870,"end":2874},"obj":"DT"},{"id":"tok533","span":{"begin":2875,"end":2886},"obj":"JJ"},{"id":"tok534","span":{"begin":2887,"end":2899},"obj":"JJ"},{"id":"tok535","span":{"begin":2900,"end":2904},"obj":"NN"},{"id":"tok536","span":{"begin":2905,"end":2911},"obj":"NN"},{"id":"tok537","span":{"begin":2912,"end":2914},"obj":"IN"},{"id":"tok538","span":{"begin":2915,"end":2916},"obj":"CD"},{"id":"tok539","span":{"begin":2917,"end":2927},"obj":"RB"},{"id":"tok540","span":{"begin":2928,"end":2931},"obj":"JJ"},{"id":"tok541","span":{"begin":2932,"end":2940},"obj":"NNS"},{"id":"tok542","span":{"begin":2941,"end":2945},"obj":"IN"},{"id":"tok543","span":{"begin":2946,"end":2952},"obj":"NNP"},{"id":"tok544","span":{"begin":2952,"end":2954},"obj":"CD"},{"id":"tok545","span":{"begin":2955,"end":2958},"obj":"CC"},{"id":"tok546","span":{"begin":2959,"end":2963},"obj":"NNP"},{"id":"tok547","span":{"begin":2963,"end":2964},"obj":","},{"id":"tok548","span":{"begin":2965,"end":2979},"obj":"NN"},{"id":"tok549","span":{"begin":2980,"end":2982},"obj":"IN"},{"id":"tok550","span":{"begin":2983,"end":2995},"obj":"NN"},{"id":"tok551","span":{"begin":2996,"end":3002},"obj":"NN"},{"id":"tok552","span":{"begin":3003,"end":3013},"obj":"VBG"},{"id":"tok553","span":{"begin":3014,"end":3026},"obj":"VBG"},{"id":"tok554","span":{"begin":3027,"end":3035},"obj":"NN"},{"id":"tok555","span":{"begin":3036,"end":3039},"obj":"VBD"},{"id":"tok556","span":{"begin":3040,"end":3048},"obj":"VBN"},{"id":"tok557","span":{"begin":3049,"end":3051},"obj":"IN"},{"id":"tok558","span":{"begin":3052,"end":3063},"obj":"NN"},{"id":"tok559","span":{"begin":3064,"end":3066},"obj":"IN"},{"id":"tok560","span":{"begin":3067,"end":3072},"obj":"PRP$"},{"id":"tok561","span":{"begin":3073,"end":3081},"obj":"JJ"},{"id":"tok562","span":{"begin":3082,"end":3088},"obj":"NN"},{"id":"tok563","span":{"begin":3088,"end":3089},"obj":"."},{"id":"tok564","span":{"begin":3090,"end":3093},"obj":"DT"},{"id":"tok565","span":{"begin":3094,"end":3101},"obj":"JJ"},{"id":"tok566","span":{"begin":3102,"end":3108},"obj":"NN"},{"id":"tok567","span":{"begin":3109,"end":3113},"obj":"NN"},{"id":"tok568","span":{"begin":3114,"end":3117},"obj":"CC"},{"id":"tok569","span":{"begin":3118,"end":3123},"obj":"NN"},{"id":"tok570","span":{"begin":3124,"end":3130},"obj":"NN"},{"id":"tok571","span":{"begin":3131,"end":3139},"obj":"VB"},{"id":"tok572","span":{"begin":3140,"end":3141},"obj":"DT"},{"id":"tok573","span":{"begin":3142,"end":3152},"obj":"JJ"},{"id":"tok574","span":{"begin":3153,"end":3162},"obj":"NN"},{"id":"tok575","span":{"begin":3163,"end":3168},"obj":"IN"},{"id":"tok576","span":{"begin":3169,"end":3172},"obj":"DT"},{"id":"tok577","span":{"begin":3173,"end":3182},"obj":"JJ"},{"id":"tok578","span":{"begin":3183,"end":3196},"obj":"NN"},{"id":"tok579","span":{"begin":3197,"end":3199},"obj":"IN"},{"id":"tok580","span":{"begin":3200,"end":3204},"obj":"DT"},{"id":"tok581","span":{"begin":3205,"end":3214},"obj":"NN"},{"id":"tok582","span":{"begin":3214,"end":3215},"obj":","},{"id":"tok583","span":{"begin":3216,"end":3219},"obj":"CC"},{"id":"tok584","span":{"begin":3220,"end":3225},"obj":"DT"},{"id":"tok585","span":{"begin":3226,"end":3238},"obj":"NNS"},{"id":"tok586","span":{"begin":3239,"end":3246},"obj":"VBP"},{"id":"tok587","span":{"begin":3247,"end":3257},"obj":"NN"},{"id":"tok588","span":{"begin":3258,"end":3260},"obj":"IN"},{"id":"tok589","span":{"begin":3261,"end":3269},"obj":"JJ"},{"id":"tok590","span":{"begin":3270,"end":3276},"obj":"NNS"},{"id":"tok591","span":{"begin":3276,"end":3277},"obj":"."},{"id":"tok592","span":{"begin":922,"end":924},"obj":"POS"},{"id":"lookup1","span":{"begin":39,"end":43},"obj":"stop"},{"id":"lookup2","span":{"begin":53,"end":57},"obj":"stop"},{"id":"lookup3","span":{"begin":111,"end":115},"obj":"year"},{"id":"lookup4","span":{"begin":127,"end":129},"obj":"country_code"},{"id":"lookup5","span":{"begin":146,"end":148},"obj":"country_code"},{"id":"lookup6","span":{"begin":204,"end":206},"obj":"stop"},{"id":"lookup7","span":{"begin":207,"end":209},"obj":"country_code"},{"id":"lookup8","span":{"begin":219,"end":221},"obj":"country_code"},{"id":"lookup9","span":{"begin":311,"end":313},"obj":"country_code"},{"id":"lookup10","span":{"begin":325,"end":327},"obj":"country_code"},{"id":"lookup11","span":{"begin":446,"end":452},"obj":"org_key"},{"id":"lookup12","span":{"begin":863,"end":865},"obj":"country_code"},{"id":"lookup13","span":{"begin":889,"end":899},"obj":"org_base"},{"id":"lookup14","span":{"begin":901,"end":909},"obj":"location"},{"id":"lookup15","span":{"begin":925,"end":933},"obj":"org_base"},{"id":"lookup16","span":{"begin":934,"end":936},"obj":"country_code"},{"id":"lookup17","span":{"begin":937,"end":945},"obj":"location"},{"id":"lookup18","span":{"begin":947,"end":952},"obj":"location"},{"id":"lookup19","span":{"begin":959,"end":966},"obj":"date"},{"id":"lookup20","span":{"begin":971,"end":975},"obj":"year"},{"id":"lookup21","span":{"begin":977,"end":979},"obj":"country_code"},{"id":"lookup22","span":{"begin":980,"end":985},"obj":"location"},{"id":"lookup23","span":{"begin":980,"end":985},"obj":"date"},{"id":"lookup24","span":{"begin":990,"end":994},"obj":"year"},{"id":"lookup25","span":{"begin":1024,"end":1029},"obj":"location"},{"id":"lookup26","span":{"begin":1024,"end":1029},"obj":"date"},{"id":"lookup27","span":{"begin":1034,"end":1038},"obj":"year"},{"id":"lookup28","span":{"begin":1291,"end":1293},"obj":"country_code"},{"id":"lookup29","span":{"begin":1329,"end":1334},"obj":"organization"},{"id":"lookup30","span":{"begin":1329,"end":1334},"obj":"person_first"},{"id":"lookup31","span":{"begin":1530,"end":1534},"obj":"date_unit"},{"id":"lookup32","span":{"begin":1971,"end":1976},"obj":"date_unit"},{"id":"lookup33","span":{"begin":2025,"end":2027},"obj":"country_code"},{"id":"lookup34","span":{"begin":2179,"end":2183},"obj":"date_unit"},{"id":"lookup35","span":{"begin":2184,"end":2186},"obj":"country_code"},{"id":"lookup36","span":{"begin":2264,"end":2268},"obj":"date_unit"},{"id":"lookup37","span":{"begin":2369,"end":2373},"obj":"date_unit"},{"id":"lookup38","span":{"begin":2421,"end":2426},"obj":"organization"},{"id":"lookup39","span":{"begin":2421,"end":2426},"obj":"person_first"},{"id":"lookup40","span":{"begin":2531,"end":2534},"obj":"date_unit"},{"id":"lookup41","span":{"begin":2553,"end":2555},"obj":"country_code"},{"id":"lookup42","span":{"begin":2567,"end":2569},"obj":"country_code"},{"id":"lookup43","span":{"begin":2573,"end":2577},"obj":"date_unit"},{"id":"lookup44","span":{"begin":2661,"end":2666},"obj":"date_unit"},{"id":"lookup45","span":{"begin":2681,"end":2683},"obj":"stop"},{"id":"lookup46","span":{"begin":2773,"end":2777},"obj":"date_unit"},{"id":"lookup47","span":{"begin":2790,"end":2792},"obj":"country_code"},{"id":"lookup48","span":{"begin":2810,"end":2812},"obj":"country_code"},{"id":"lookup49","span":{"begin":2816,"end":2820},"obj":"date_unit"},{"id":"lookup50","span":{"begin":2870,"end":2874},"obj":"time_modifier"},{"id":"lookup51","span":{"begin":3049,"end":3051},"obj":"country_code"},{"id":"lookup52","span":{"begin":3064,"end":3066},"obj":"country_code"},{"id":"lookup53","span":{"begin":3200,"end":3204},"obj":"time_modifier"},{"id":"lookup54","span":{"begin":3258,"end":3260},"obj":"country_code"},{"id":"event1","span":{"begin":2712,"end":2722},"obj":"OCCURRENCE"},{"id":"event2","span":{"begin":3003,"end":3013},"obj":"OCCURRENCE"},{"id":"event3","span":{"begin":2219,"end":2228},"obj":"OCCURRENCE"},{"id":"event4","span":{"begin":608,"end":611},"obj":"OCCURRENCE"},{"id":"event5","span":{"begin":2470,"end":2479},"obj":"OCCURRENCE"},{"id":"event6","span":{"begin":1870,"end":1878},"obj":"OCCURRENCE"},{"id":"event7","span":{"begin":1690,"end":1700},"obj":"OCCURRENCE"},{"id":"event8","span":{"begin":1992,"end":2001},"obj":"OCCURRENCE"},{"id":"event9","span":{"begin":2329,"end":2338},"obj":"OCCURRENCE"},{"id":"event10","span":{"begin":222,"end":226},"obj":"OCCURRENCE"},{"id":"event11","span":{"begin":2244,"end":2253},"obj":"OCCURRENCE"},{"id":"event12","span":{"begin":1421,"end":1429},"obj":"OCCURRENCE"},{"id":"event13","span":{"begin":1499,"end":1511},"obj":"OCCURRENCE"},{"id":"event14","span":{"begin":3040,"end":3048},"obj":"OCCURRENCE"},{"id":"event15","span":{"begin":2544,"end":2552},"obj":"OCCURRENCE"},{"id":"event16","span":{"begin":1142,"end":1150},"obj":"OCCURRENCE"},{"id":"event17","span":{"begin":1450,"end":1459},"obj":"OCCURRENCE"},{"id":"event18","span":{"begin":2460,"end":2469},"obj":"OCCURRENCE"},{"id":"event19","span":{"begin":793,"end":800},"obj":"OCCURRENCE"},{"id":"event20","span":{"begin":3131,"end":3139},"obj":"OCCURRENCE"},{"id":"event21","span":{"begin":257,"end":266},"obj":"OCCURRENCE"},{"id":"event22","span":{"begin":2062,"end":2070},"obj":"OCCURRENCE"},{"id":"event23","span":{"begin":853,"end":862},"obj":"OCCURRENCE"},{"id":"event24","span":{"begin":2343,"end":2349},"obj":"OCCURRENCE"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-HP-v1","denotations":[{"id":"T1","span":{"begin":567,"end":587},"obj":"Phenotype"},{"id":"T2","span":{"begin":643,"end":652},"obj":"Phenotype"},{"id":"T3","span":{"begin":1580,"end":1607},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0004370"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T1","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":117,"end":125},"obj":"Disease"},{"id":"T4","span":{"begin":374,"end":421},"obj":"Disease"},{"id":"T5","span":{"begin":374,"end":407},"obj":"Disease"},{"id":"T6","span":{"begin":423,"end":431},"obj":"Disease"},{"id":"T7","span":{"begin":435,"end":444},"obj":"Disease"},{"id":"T8","span":{"begin":548,"end":556},"obj":"Disease"},{"id":"T9","span":{"begin":561,"end":596},"obj":"Disease"},{"id":"T10","span":{"begin":567,"end":596},"obj":"Disease"},{"id":"T11","span":{"begin":598,"end":602},"obj":"Disease"},{"id":"T12","span":{"begin":643,"end":652},"obj":"Disease"},{"id":"T13","span":{"begin":870,"end":888},"obj":"Disease"},{"id":"T14","span":{"begin":1195,"end":1203},"obj":"Disease"},{"id":"T15","span":{"begin":1465,"end":1473},"obj":"Disease"},{"id":"T16","span":{"begin":1801,"end":1805},"obj":"Disease"},{"id":"T17","span":{"begin":2401,"end":2409},"obj":"Disease"},{"id":"T18","span":{"begin":2539,"end":2543},"obj":"Disease"},{"id":"T19","span":{"begin":2946,"end":2954},"obj":"Disease"},{"id":"T20","span":{"begin":2959,"end":2963},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T1","span":{"begin":71,"end":77},"obj":"Body_part"},{"id":"T2","span":{"begin":288,"end":294},"obj":"Body_part"},{"id":"T3","span":{"begin":819,"end":825},"obj":"Body_part"},{"id":"T4","span":{"begin":1102,"end":1108},"obj":"Body_part"},{"id":"T5","span":{"begin":1181,"end":1187},"obj":"Body_part"},{"id":"T6","span":{"begin":1215,"end":1223},"obj":"Body_part"},{"id":"T7","span":{"begin":1225,"end":1228},"obj":"Body_part"},{"id":"T8","span":{"begin":1488,"end":1494},"obj":"Body_part"},{"id":"T9","span":{"begin":1591,"end":1595},"obj":"Body_part"},{"id":"T10","span":{"begin":1620,"end":1625},"obj":"Body_part"},{"id":"T11","span":{"begin":1746,"end":1751},"obj":"Body_part"},{"id":"T12","span":{"begin":1752,"end":1760},"obj":"Body_part"},{"id":"T13","span":{"begin":1776,"end":1781},"obj":"Body_part"},{"id":"T14","span":{"begin":1909,"end":1915},"obj":"Body_part"},{"id":"T15","span":{"begin":2122,"end":2128},"obj":"Body_part"},{"id":"T16","span":{"begin":2142,"end":2146},"obj":"Body_part"},{"id":"T17","span":{"begin":2444,"end":2452},"obj":"Body_part"},{"id":"T18","span":{"begin":2996,"end":3002},"obj":"Body_part"},{"id":"T19","span":{"begin":3027,"end":3035},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A83372","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A93873","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A16688","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":71,"end":77},"obj":"Body_part"},{"id":"T2","span":{"begin":288,"end":294},"obj":"Body_part"},{"id":"T3","span":{"begin":819,"end":825},"obj":"Body_part"},{"id":"T4","span":{"begin":1102,"end":1108},"obj":"Body_part"},{"id":"T5","span":{"begin":1181,"end":1187},"obj":"Body_part"},{"id":"T6","span":{"begin":1215,"end":1223},"obj":"Body_part"},{"id":"T7","span":{"begin":1225,"end":1228},"obj":"Body_part"},{"id":"T8","span":{"begin":1488,"end":1494},"obj":"Body_part"},{"id":"T9","span":{"begin":1591,"end":1595},"obj":"Body_part"},{"id":"T10","span":{"begin":1620,"end":1625},"obj":"Body_part"},{"id":"T11","span":{"begin":1746,"end":1751},"obj":"Body_part"},{"id":"T12","span":{"begin":1752,"end":1760},"obj":"Body_part"},{"id":"T13","span":{"begin":1776,"end":1781},"obj":"Body_part"},{"id":"T14","span":{"begin":1909,"end":1915},"obj":"Body_part"},{"id":"T15","span":{"begin":2122,"end":2128},"obj":"Body_part"},{"id":"T16","span":{"begin":2142,"end":2146},"obj":"Body_part"},{"id":"T17","span":{"begin":2444,"end":2452},"obj":"Body_part"},{"id":"T18","span":{"begin":2996,"end":3002},"obj":"Body_part"},{"id":"T19","span":{"begin":3027,"end":3035},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":1620,"end":1625},"obj":"Body_part"},{"id":"T2","span":{"begin":1746,"end":1751},"obj":"Body_part"},{"id":"T3","span":{"begin":1776,"end":1781},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid_AGAC","denotations":[{"id":"p118680s3","span":{"begin":2329,"end":2338},"obj":"NegReg"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":117,"end":125},"obj":"Disease"},{"id":"T4","span":{"begin":374,"end":421},"obj":"Disease"},{"id":"T5","span":{"begin":374,"end":407},"obj":"Disease"},{"id":"T6","span":{"begin":423,"end":431},"obj":"Disease"},{"id":"T7","span":{"begin":435,"end":444},"obj":"Disease"},{"id":"T8","span":{"begin":548,"end":556},"obj":"Disease"},{"id":"T9","span":{"begin":561,"end":596},"obj":"Disease"},{"id":"T10","span":{"begin":567,"end":596},"obj":"Disease"},{"id":"T11","span":{"begin":598,"end":602},"obj":"Disease"},{"id":"T12","span":{"begin":643,"end":652},"obj":"Disease"},{"id":"T13","span":{"begin":870,"end":888},"obj":"Disease"},{"id":"T14","span":{"begin":1195,"end":1203},"obj":"Disease"},{"id":"T15","span":{"begin":1465,"end":1473},"obj":"Disease"},{"id":"T16","span":{"begin":1801,"end":1805},"obj":"Disease"},{"id":"T17","span":{"begin":2401,"end":2409},"obj":"Disease"},{"id":"T18","span":{"begin":2539,"end":2543},"obj":"Disease"},{"id":"T19","span":{"begin":2946,"end":2954},"obj":"Disease"},{"id":"T20","span":{"begin":2959,"end":2963},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":71,"end":77},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T2","span":{"begin":130,"end":131},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":243,"end":252},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T4","span":{"begin":288,"end":294},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T5","span":{"begin":819,"end":825},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T6","span":{"begin":1102,"end":1108},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T7","span":{"begin":1181,"end":1187},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T8","span":{"begin":1193,"end":1194},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":1341,"end":1342},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":1488,"end":1494},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T11","span":{"begin":1527,"end":1529},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T12","span":{"begin":1620,"end":1625},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T13","span":{"begin":1776,"end":1781},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T14","span":{"begin":1776,"end":1781},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T15","span":{"begin":1842,"end":1850},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T16","span":{"begin":1909,"end":1915},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T17","span":{"begin":1965,"end":1967},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T18","span":{"begin":2122,"end":2128},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T19","span":{"begin":2996,"end":3002},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T20","span":{"begin":3140,"end":3141},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":717,"end":726},"obj":"Chemical"},{"id":"T2","span":{"begin":2071,"end":2087},"obj":"Chemical"},{"id":"T3","span":{"begin":2092,"end":2110},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":78},"obj":"Sentence"},{"id":"T2","span":{"begin":79,"end":90},"obj":"Sentence"},{"id":"T3","span":{"begin":91,"end":203},"obj":"Sentence"},{"id":"T4","span":{"begin":204,"end":242},"obj":"Sentence"},{"id":"T5","span":{"begin":243,"end":253},"obj":"Sentence"},{"id":"T6","span":{"begin":254,"end":445},"obj":"Sentence"},{"id":"T7","span":{"begin":446,"end":480},"obj":"Sentence"},{"id":"T8","span":{"begin":481,"end":781},"obj":"Sentence"},{"id":"T9","span":{"begin":782,"end":838},"obj":"Sentence"},{"id":"T10","span":{"begin":839,"end":1039},"obj":"Sentence"},{"id":"T11","span":{"begin":1040,"end":1121},"obj":"Sentence"},{"id":"T12","span":{"begin":1122,"end":1132},"obj":"Sentence"},{"id":"T13","span":{"begin":1133,"end":1474},"obj":"Sentence"},{"id":"T14","span":{"begin":1475,"end":1551},"obj":"Sentence"},{"id":"T15","span":{"begin":1552,"end":1579},"obj":"Sentence"},{"id":"T16","span":{"begin":1580,"end":1928},"obj":"Sentence"},{"id":"T17","span":{"begin":1929,"end":1937},"obj":"Sentence"},{"id":"T18","span":{"begin":1938,"end":2111},"obj":"Sentence"},{"id":"T19","span":{"begin":2112,"end":2311},"obj":"Sentence"},{"id":"T20","span":{"begin":2312,"end":2538},"obj":"Sentence"},{"id":"T21","span":{"begin":2539,"end":2680},"obj":"Sentence"},{"id":"T22","span":{"begin":2681,"end":2757},"obj":"Sentence"},{"id":"T23","span":{"begin":2758,"end":2839},"obj":"Sentence"},{"id":"T24","span":{"begin":2840,"end":2866},"obj":"Sentence"},{"id":"T25","span":{"begin":2867,"end":3089},"obj":"Sentence"},{"id":"T26","span":{"begin":3090,"end":3277},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3","span":{"begin":15,"end":29},"obj":"Disease"},{"id":"4","span":{"begin":30,"end":38},"obj":"Species"},{"id":"5","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"41","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"42","span":{"begin":117,"end":125},"obj":"Disease"},{"id":"43","span":{"begin":193,"end":202},"obj":"Disease"},{"id":"44","span":{"begin":345,"end":359},"obj":"Disease"},{"id":"45","span":{"begin":360,"end":368},"obj":"Species"},{"id":"46","span":{"begin":374,"end":421},"obj":"Species"},{"id":"47","span":{"begin":423,"end":433},"obj":"Species"},{"id":"48","span":{"begin":435,"end":444},"obj":"Disease"},{"id":"49","span":{"begin":467,"end":479},"obj":"Species"},{"id":"50","span":{"begin":498,"end":512},"obj":"Disease"},{"id":"51","span":{"begin":513,"end":521},"obj":"Species"},{"id":"52","span":{"begin":548,"end":556},"obj":"Disease"},{"id":"53","span":{"begin":561,"end":596},"obj":"Disease"},{"id":"54","span":{"begin":598,"end":602},"obj":"Disease"},{"id":"55","span":{"begin":643,"end":652},"obj":"Disease"},{"id":"56","span":{"begin":870,"end":888},"obj":"Disease"},{"id":"57","span":{"begin":916,"end":922},"obj":"Species"},{"id":"58","span":{"begin":1133,"end":1141},"obj":"Species"},{"id":"59","span":{"begin":1195,"end":1205},"obj":"Species"},{"id":"60","span":{"begin":1437,"end":1445},"obj":"Species"},{"id":"61","span":{"begin":1465,"end":1473},"obj":"Disease"},{"id":"62","span":{"begin":1801,"end":1805},"obj":"Disease"},{"id":"63","span":{"begin":1944,"end":1952},"obj":"Species"},{"id":"64","span":{"begin":1980,"end":1985},"obj":"Species"},{"id":"65","span":{"begin":2092,"end":2110},"obj":"Chemical"},{"id":"66","span":{"begin":2194,"end":2202},"obj":"Species"},{"id":"67","span":{"begin":2401,"end":2411},"obj":"Species"},{"id":"68","span":{"begin":2539,"end":2543},"obj":"Disease"},{"id":"69","span":{"begin":2558,"end":2566},"obj":"Species"},{"id":"70","span":{"begin":2603,"end":2611},"obj":"Species"},{"id":"71","span":{"begin":2690,"end":2698},"obj":"Species"},{"id":"72","span":{"begin":2917,"end":2931},"obj":"Disease"},{"id":"73","span":{"begin":2932,"end":2940},"obj":"Species"},{"id":"74","span":{"begin":2946,"end":2954},"obj":"Disease"},{"id":"75","span":{"begin":2959,"end":2963},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:D016638"},{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"Tax:9606"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:C000657245"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:C000657245"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:C000657245"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D003643"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D016638"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"Tax:9606"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:2697049"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:2697049"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D007239"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:9606"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D016638"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:9606"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:C000657245"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D012128"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D012128"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:D011014"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D003141"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"Tax:9606"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"Tax:9606"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:2697049"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:9606"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:C000657245"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D012128"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:9606"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"Tax:9606"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D008775"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"Tax:9606"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"Tax:2697049"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D012128"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"Tax:9606"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"Tax:9606"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"Tax:9606"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:D016638"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"Tax:9606"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:C000657245"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":567,"end":587},"obj":"Phenotype"},{"id":"T2","span":{"begin":643,"end":652},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\nImportance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.\nObjective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nDesign, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 \u003c300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.\nExposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.\nMain Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.\nResults: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.\nConclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials."}